One pill to shield the heart? a polypill aims to prevent heart failure in diabetes

NCT ID NCT06143566

Recruiting now Prevention Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial tests whether a single polypill combining three medications—finerenone, empagliflozin, and losartan—can help prevent heart failure and maintain exercise capacity in people with type 2 diabetes who are at high risk. Participants will take either the polypill or the same three drugs separately for six months. The study will measure changes in peak oxygen uptake during exercise and how well people stick to their medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A combination pill containing finerenone, empagliflozin, and losartan
What this could lead to: If successful, this could offer a simple, once-daily pill to help prevent heart failure and preserve exercise capacity in people with type 2 diabetes at high risk.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. The polypill may not improve adherence or outcomes as hoped, and there are potential side effects from the medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH BLOOD PRESSURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Diabetic Cardiomyopathies hypertensive disorder type 2 diabetes mellitus heart failure prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH BLOOD PRESSURE TYPE 2 DIABETES

Contacts and locations

Locations

UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.